Home/Pipeline/MK-5684

MK-5684

Metastatic Castration-Resistant Prostate Cancer

Phase 3Active, Ongoing

Key Facts

Indication

Metastatic Castration-Resistant Prostate Cancer

Phase

Phase 3

Status

Active, Ongoing

Company

Merck

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

Therapeutic Areas

Oncology Vaccines Immunology Cardiometabolic Infectious Diseases Neuroscience

Other Metastatic Castration-Resistant Prostate Cancer Drugs

Drug	Company	Phase	Status
KEYTRUDA (pembrolizumab)	Merck	Phase 3	Active, Ongoing
TAK-280	Thermo Fisher Scientific	Phase 2	Active, not recruiting
PNT2001	Lantheus Holdings	Phase 3	Active
ARV-766	Arvinas	Phase 2	Active
Bavdegalutamide (ARV-110)	Arvinas	Phase 2	Active